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Fig. 1. Outcome of biochemical and virological parameters.To the Editor:
Genotype 3 hepatitis E virus (HEV3) infection is responsible for
self-limiting acute hepatitis, chronic HEV3 infection leading to
cirrhosis in immunosuppressed patients, and several extra-hepa-
tic manifestations, i.e., neurological symptoms, kidney injury, and
severe thrombocytopenia [1–5]. Ribavirin therapy has been
shown to be an efﬁcient therapy for chronic HEV infection [6,7].
Herein, we report on a ﬁrst case of Guillain–Barré syndrome
associated with severe necrotizing myositis that occurred in a
liver-transplant patient in acute HEV-infection phase, who then
recovered after ribavirin therapy.
A 65-year-old liver-transplant male presented, 7 years after
transplantation for alcoholic liver disease, with an autochtho-
nous acute HEV infection (Fig. 1): jaundice, increased liver-
enzyme levels, positive serum HEV RNA (126,000 copies/ml,
genotype 3f), and positive anti-HEV IgG and IgM (Wantai Bio-
logic Pharmacy Enterprise, Beijing, People’s Republic of China).
All other causes of hepatitis were ruled out. The source of HEV
infection has not been clearly identiﬁed. However, the patient
had eaten undercooked pork meat. He was receiving cyclospor-
ine A (C2 level at 600 ng/ml), mycophenolatemofetil, and ste-
roids. Cyclosporine A doses were dramatically decreased (C2
level at 300 ng/ml). Ten days later, he was unable to stand
upright.
Neurological examination showed severe quadriparesis, with
proximal muscle weakness and abolition of biceps, patellar,
and Achilles’ tendon reﬂexes, as well as a right lower facial
palsy. Creatine kinase (CK) level was increased to 191,603 IU/
L (normal <170 IU/L). Electrophysiological studies showed signs
of peripheral demyelinating polyradiculopathy with abolition or
prolongation of F-wave responses and sensory conduction was
altered more in upper limbs. At rest, needle electromyography
showed diffuse abnormal spontaneous activity in all four limbs.
Cerebrospinal-ﬂuid (CSF) analysis showed elevated protein
level (0.64 g/L), no leukocytes, and no HEV RNA, whereas
serum HEV RNA was still positive (49,600 copies/ml). The CSF
to serum-albumin ratio was 12.81. The CSF (IgG:albumin) to
serum (IgG:albumin) ratio was 0.47. Cryoglobulinemia, serum
anti-ganglioside (GM1, GM-2, GM-3, GM4, GD1A, GD1B, GD2,
GD3, GT1A, GD1B, GQ1B) antibodies, anti-myelin-associated
glycoprotein antibodies, as well as serum and CSF onconeuro-
nal antibodies, were negative. A biopsy specimen of the left
bicep brachial muscle showed myopathic changes, with a sig-
niﬁcant percentage of necrotic muscle ﬁbers (10%) and some
inﬂammatory elements. There was no capillary thickening.
The day after admission, he developed acute respiratory
failure that required mechanical ventilation. Because of sus-
pected HEV-induced Guillain–Barré syndrome associated with
severe myositis, mycophenolatemofetil was withdrawn and
the patient was given intravenous immunoglobulins (1 g/kg/d
for 2 days) and ribavirin therapy [400 mg/d adapted to his glo-Journal of Hepatology 20merular ﬁltration rate (40 ml/min)]. Rapidly after the initiation
of both therapies, CK and ALT levels decreased and returned to
within the normal range, respectively, 3 and 30 days later.
Serum HEV RNA became undetectable by day 15, but ribavirin
therapy was continued for 3 months as initially scheduled. Two
months after ribavirin was stopped, serum HEV RNA was still
negative. Fifteen days after HEV clearance, progressive recovery
of mobility was noted.
An electromyograph, performed at 2 months after initiation of
ribavirin treatment, i.e., 1.5 months after HEV clearance, showed
myopathic changes to weakmuscles. Studies on nerve conduction
showed stable demyelination and severe sensitivo-motor axonal
injury. Unfortunately, due tomechanical ventilation, he developed
a pulmonary infection that evolved to septic shock, which was
complicated by ischemic necrosis of the cecum. Currently, he con-
tinues rehabilitation and is being weaned off mechanical
ventilation.
HEV-induced Guillain–Barré has been previously reported [3].
However, this is the ﬁrst case of HEV-induced severe myositis.
Similar to HCV-induced myositis [8], in the present case, Guil-
lain–Barré syndrome and severe myositis seem to be related to
an auto-immune response. Interestingly, the use of ribavirin
allowed rapid clearance of HEV infection, which may have accel-
erated the neurological and muscle recovery.12 vol. 57 j 1152–1159
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non-alcoholic fatty liver disease: A
To the Editor:
We read with great interest the article by Chung et al. [1] show-
ing that subclinical hypothyroidism, even in the range of upper
normal thyroid stimulating hormone (TSH) levels, was closely
associated with non-alcoholic fatty liver disease (NAFLD) in a
dose-dependent manner. Their results indeed provided impor-
tant evidence, conﬁrming the close relationship between these
two diseases. However, as mentioned by the authors, the causal
relationship between hypothyroidism and NAFLD could not be
identiﬁed by their cross-sectional study.
Recently, we have performed a prospective case-control study
to evaluate the impact of subclinical hypothyroidism on the
development of NAFLD in a Chinese population. The study was
conducted among the employees of Zhenhai Reﬁning & Chemical
Company Ltd., Ningbo, China, since 2006. The study population
was described in detail in our previous studies [2,3]. A total of
327 subclinical hypothyroidism subjects were enrolled. Age, gen-
der, and body mass index (BMI) are three major factors that may
inﬂuence the development of NAFLD. To reduce the inﬂuence of
these variables, we randomly selected 327 age, gender, and BMI
matched euthyroid subjects as controls.
All the subjects were free of NAFLD at baseline, and did not
have a history of excessive alcohol consumption or liver disease.
Subclinical hypothyroidism was deﬁned as a TSH level of
4.5 mIU/L or greater, after excluding subjects with an abnormal
thyroxine level [4,5]. NAFLD was diagnosed based on the results
of abdominal ultrasonography, after exclusion of alcohol con-
sumption, viral, or autoimmune liver disease [6,7]. The develop-
ment of NAFLD was evaluated annually during follow-up by
ultrasound examination, using a Toshiba Nemio 20 sonography
Journal of Hepatology 201[8] Di Muzio A, Bonetti B, Capasso M, Panzeri L, Pizzigallo E, Rizzuto N, et al.
Hepatitis C virus infection and myositis: a virus localization study. Neuro-
muscul Disord 2003;13:68–71.idism on the development of
prospective case-control study
machine with a 3.5-MHz probe (Toshiba, Tokyo, Japan). Ultra-
sound studies were carried out by experienced ultrasonogra-
phists who were blinded to the clinical and laboratory data.
A total of 63 subclinical hypothyroidism subjects and 35
euthyroid subjects developed NAFLD during a median follow-up
of 4.92 years. Compared to the euthyroid subjects, the incidence
of NAFLD for 1000 person-years of follow-up was signiﬁcantly
higher in the subjects with subclinical hypothyroidism (38.3 vs.
21.8; p <0.05).
Subclinical hypothyroidism subjects were further classiﬁed
into three subgroups according to their TSH levels: 4.5–
6.9 mIU/L (mild elevation), 7.0–9.9 mIU/L (moderate elevation),
and 10.0 mIU/L or greater (severe elevation). The incidence of
NAFLD showed an increased trend with increasing TSH levels.
The incidence of NAFLD per 1000 person-years of follow-up
was 21.8, 34.2, 48.3 and 52.5 for the euthyroid, mild, moderate
and severe elevation subgroup, respectively (p <0.05 for trend).
This observation indicated that subjects with higher baseline
TSH levels are more likely to develop NAFLD during the follow-
up period.
Cox proportional hazards regression analyses were used to
estimate hazard ratios for incident NAFLD for subclinical hypo-
thyroidism over the follow-up period. Our analysis showed that
subclinical hypothyroidism was a risk factor for the development
of NAFLD in the unadjusted model, the hazard ratio (95% CI) was
1.77 (1.17–2.67). The metabolic syndrome is a major mediating
variable for the studied relationship. Therefore, we further
adjusted the indicators of the metabolic syndrome in the Cox pro-
portional hazards regression analysis. Our result showed that the
relationship of subclinical hypothyroidism with incident NAFLD
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